Allergy & Immunology

Is there utility when classic inflammatory markers (ESR,CRP) or disease specific markers (C3, C4, dsDNA) do not correlate with patients disease activi...

1 Answer available

How do you decide when to obtain genetic testing for suspected autoinflammatory conditions in adults?

2 Answers available

Do you diagnose obstruction by the criteria of FEV1/FVC < 70% or < LLN?

5 Answers available

How would you work up a patient with cutaneous mastocytosis?

Is a BM biopsy a must when there is skin involvement? If tryptase level is mildly elevated but less than 20 would you recommend a BM biopsy?

1 Answer available

What is your approach to working up diarrhea in an immunocompromised patient?

1 Answer available

Do you utilize post-vaccination IgG titers to detect common variable immunodeficiency in patients who are about to start or are actively on B cell depleting therapy?

2 Answers available

Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?

4 Answers available

Is there a role for biologics to help patients with ABPA who are steroid responsive and have removed their allergen insult, but continue to have an elevated serum IgE and incomplete resolution of symptoms return to their baseline functional status?

1 Answer available

Is there a role for the use of biologics as steroid sparing agents in treating patients with ABPA who are intolerant to prednisone?

1 Answer available

What is your approach to checking IgG levels post vaccination to detect common variable immunodeficiency in patients with systemic lupus?

If a deficiency is present, do you consider IVIG to treat non-infectious symptoms such as skin rash, arthritis or hematological abnormalities?

1 Answer available

Is there a role for biologic therapies in asthma-COPD overlap syndrome with evidence of type 2 inflammation?

2 Answers available

With the approval of oral JAK inhibitors such as Upadacitinib for atopic dermatitis, how are you considering its safety profile in comparison to traditional immunosuppressants such as prednisone, methotrexate, azathioprine, and mycophenolate?

Especially in the setting of these being more narrow acting than tofacitinib, should we consider them safer than our old drugs?

2 Answers available

How do you treat post-IVIG headache that is not responsive to Tylenol or NSAIDs?

Specifically, how do you treat the delayed headache, not the headache that develops during the infusion where pre-hydration and slowing down the rate ...

4 Answers available

Is there a role for antibody testing to confirm vaccine response for patients on rituximab after COVID-19 vaccination?

1 Answer available

Is it okay to use medications associated with drug-induced lupus in patients with SLE?

1 Answer available

How does a history of splenectomy alter how you counsel patients on the infection risk of TNF inhibitors or other biologics?

1 Answer available

For which rituximab infusion reaction symptoms do you consider it safe to re-challenge in the office with adjusted rates and pre-medications?

1 Answer available

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?

2 Answers available

How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?